Isolation Or Purification Patents (Class 530/305)
-
Patent number: 10617975Abstract: The present invention refers to a method for the separation of peptide aggregates and fragments from solutions containing target peptide.Type: GrantFiled: November 18, 2015Date of Patent: April 14, 2020Assignee: MERCK PATENT GMBHInventors: Romas Skudas, Klaus Adrian, Bianca Edelmann, Matthias Joehnck
-
Publication number: 20150045533Abstract: The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material.Type: ApplicationFiled: September 17, 2012Publication date: February 12, 2015Inventors: Markus Arendt, Björn Degel, Thomas Schwarz, Gerhard Stumm, Martin Welter
-
Publication number: 20140336355Abstract: The present invention relates to a crosslinked sulphonated polymer or a crosslinked sulphonated polymer coated with a crosslinked polymer containing amino groups for use as an ion exchanger material of high salt tolerance for separating off macromolecules from a solution which originates from a biological source.Type: ApplicationFiled: July 12, 2012Publication date: November 13, 2014Applicant: INSTRACTION GMBHInventors: Markus Arendt, Gerhard Stumm, Martin Welter, Thomas Schwarz
-
Publication number: 20140323687Abstract: The present invention relates to a method for the isolation of proteins that comprise disulfide-bonds in their native conformation. Essentially, a method of the present makes the use of reducing agents such as ?-mercaptoethanol or dithiothreitol in protein isolation methods obsolete. A method of the present invention is particularly suitable for the isolation of precursor proteins such as proinsulin from recombinant cells.Type: ApplicationFiled: July 8, 2014Publication date: October 30, 2014Inventors: Peter Van Der Meijden, Gijsbert Willem Karel Van Dedem, Michel Hendrikus Maria Eppink, Roeland Wilhelmus Wassenaar
-
Publication number: 20140243498Abstract: The present invention is within the field of biomolecule purification. More closely the invention relates to chromatographic purification of insulin using a specific kind of shell beads having an inner core and an outer functionalized layer. The method enables purification at high flow rates and high purity, over 90%.Type: ApplicationFiled: September 28, 2012Publication date: August 28, 2014Inventors: Eggert Brekkan, Kjell Eriksson, Bo-Lennart Johansson, Jamil Shanagar
-
Publication number: 20140228539Abstract: The invention relates to a process for separating acetylated proteins from unacetylated proteins. In particular, the invention relates to a process of using multimodal chromatography to separate acetylated proteins from unacetylated proteins. In the prior art, multimodal chromatography is used to isolate antibodies. The invention found that multimodal chromatography can be used in the separation of acetylated proteins from unacetylated proteins.Type: ApplicationFiled: April 18, 2014Publication date: August 14, 2014Applicants: TANVEX BIOLOGICS CORP., LA JOLLA BIOLOGICS, INC.Inventors: Kuo-Ming YU, Judy Huei-chuan CHOU, Jennifer Renee HOPP
-
Patent number: 8802816Abstract: The invention relates to methods of separation and/or purification of impurities yielding a purified heterologous protein product devoid of related impurities or with substantially minimal quantities of such glycosylated impurities. More specifically, the invention relates to the identification of glycosylated forms of insulin analogues such as glargine impurities characterized post expression in yeast based systems such as Pichia pastoris. The invention also relates to methods used to clone gene encoding the protein insulin glargine; inserting the related gene in a suitable yeast host; producing culture of the recombinant strain, stimulating expression of the heterologous polypeptide, its secretion and purification post fermentation and related enzymatic conversions.Type: GrantFiled: April 3, 2008Date of Patent: August 12, 2014Assignee: Biocon LimitedInventors: Partha Hazra, Nitesh Dave, Vivekanandan Kannan, Sanjay Tiwari, Anuj Goel, Harish Iyer, Nita Roy, Krishnamurthy Venkatesan, Anoop Vasudevan, Anupama Jagadish, Goldy Sachdev, Mukesh Babuappa Patale
-
Publication number: 20140155574Abstract: Disclosed is a method for preparing an insulin glargine (GlyA21-ArgB31-AryB32-human insulin) crystal, comprising crystallizing the insulin glargine at pH 7.0-9.0 and in a crystallization solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid.Type: ApplicationFiled: April 19, 2012Publication date: June 5, 2014Applicant: GAN & LEE PHARMACEUTICALSInventors: Damei Wang, Wenjie Li, Jinlei Zhang
-
Publication number: 20140073759Abstract: The present application discloses a chromatographic process for separating protein components of a protein-containing solution, said solution comprising an insulin peptide and one or more di- or polyvalent metal ions, said insulin peptide being capable of self-association and/or structural change in the presence of di- or polyvalent metal ions, said process comprising the steps of: a) applying the protein-containing solution to a column of a chromatographic solid phase material, wherein the loading of the insulin peptide is at least 6.0 g per litre of column volume (g/Lcv); and b) eluting the insulin peptide from said solid phase material by means of an eluent having a pH of at the most 8.5; and collecting a pool of the insulin peptide corresponding to at least 75% by weight of the insulin peptide applied to the column in step (a).Type: ApplicationFiled: February 1, 2012Publication date: March 13, 2014Applicant: Novo Nordisk A/SInventors: Joergen M. Mollerup, Soeren Soendergaarad Frederiksen
-
Patent number: 8669418Abstract: The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein. The present invention also discloses such interferor molecules and their use in agrobiotech applications.Type: GrantFiled: May 6, 2011Date of Patent: March 11, 2014Assignees: VIB VZW, Vrije Universiteit BrusselInventors: Joost Schymkowitz, Frederic Rousseau
-
Publication number: 20130338064Abstract: Provided are an insulin-lipid complex, a preparation method thereof, and a formulation thereof. The insulin-lipid complex is prepared by compounding insulin and a lipid material in an organic solvent system containing a low boiling point acid, and drying. The mass ratio of insulin to the lipid material is 1:3˜1:20. An oil solution of the insulin-lipid complex and vesicles containing insulin are further provided.Type: ApplicationFiled: July 14, 2011Publication date: December 19, 2013Applicant: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Yuling Liu, Cuiping Zhou, Zhihui Song, Lin Li, Hongliang Wang, Xuejun Xia, Renyun Wang, Wujun Dong, Dujia Jin
-
Publication number: 20130323812Abstract: Methods and compositions are provided for treatment of an apatite-based resin from which retained solutes have been eluted by an elution buffer that contains an alkali metal salt with solutions of calcium ion, phosphate ion, and hydroxide separately from any sample loading and elution buffers. The treatment solutions restore the resin, reversing the deterioration that is caused by the alkali metal salt in the elution buffer.Type: ApplicationFiled: May 10, 2013Publication date: December 5, 2013Applicant: Bio-Rad Laboratories, Inc.Inventors: Larry J. Cummings, Jie He
-
Patent number: 8569227Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: April 29, 2011Date of Patent: October 29, 2013Assignee: Janssen Biotech, Inc.Inventor: Steven Jacobs
-
Publication number: 20130150553Abstract: The present invention relates to a method for the isolation of proteins that comprise disulfide bonds in their native conformation. Essentially, a method of the present invention makes use of reducing agents such as ?-mercaptoethanol or dithiothreitol in protein isolation methods obsolete. A method of the present invention is particularly suitable for the isolation of precursor proteins such as proinsulin from recombinant cells.Type: ApplicationFiled: May 9, 2012Publication date: June 13, 2013Inventors: Peter Van Der Meijden, Gijsbert Willem Karel Van Dedem, Michel Hendrikus Maria Eppink, Roeland Wilhelmus Wassenaar
-
Publication number: 20130012684Abstract: The present invention provides a method for purification of a protein that is conjugated to an albumin binding moiety from a mixture comprising (i) said protein in said conjugated form and (ii) said protein in a form that is not conjugated to said albumin-binding moiety, the method comprising: (a) providing a solid support comprising a substance capable of specifically binding to the albumin binding moiety; (b) contacting said solid support of (a) with said mixture comprising protein and conjugated protein under suitable conditions for binding of the albumin binding moiety to the substance as defined in (a); and (c) eluting components bound to the solid support.Type: ApplicationFiled: February 3, 2011Publication date: January 10, 2013Applicant: Novo Nordisk A/SInventor: Jens Buchardt
-
Publication number: 20120214966Abstract: A process is disclosed for separating biomolecules from an aqueous solution containing the biomolecules and impurities, having different affinities and/or interactions with a solid support. The solution is passed over a fixed bed of chromatographic resin containing at least three zones, with flow of liquid being arranged between adjacent zones and between a last and first zone. Each of several sequences includes at least an adsorption stage, a rinsing stage, or a desorption stage, with each subsequent sequence being carried out by a downstream displacement of fronts in the zones by approximately the same increment before the periodical displacement of the introduction and withdrawal points.Type: ApplicationFiled: April 17, 2012Publication date: August 23, 2012Applicant: GROUPE NOVASEPInventors: Marc-André Theoleyre, Stanislas Baudouin, Annick Merrien, Eric Valery, Olivier Ludemann-Hombourger, David Laurent, Margit Holzer
-
Publication number: 20120178900Abstract: The present disclosure demonstrates the utility of ion pairing agents in the preparative scale of purification. More particularly, the disclosure relates to the usage of ion pairing agents in RP preparative linear chromatography enabling high purity of the desired end product. The disclosure shows that ion-pairing agents have dramatic effect on desired purity of polypeptides.Type: ApplicationFiled: August 9, 2010Publication date: July 12, 2012Applicant: BIOCON LIMITEDInventors: Nitesh Dave, Krishana Chaitanya Gulla, Sundaresh Shankar, Harish Iyer
-
Publication number: 20120123089Abstract: The instant disclosure provides a method for purification of peptides by chromatographic techniques. The proposed methodology will help in addressing the problems associated in purifying biological protein products emerging from the evolving biotechnology industry.Type: ApplicationFiled: July 8, 2010Publication date: May 17, 2012Applicant: BIOCON LIMITEDInventors: Nitesh Dave, Devesh Radhakrishnan, Sundaresh Shankar, Krishanachaitanya Gulla, Harish Iyer
-
Patent number: 8058391Abstract: The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in Pichia. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated with protease and purified to afford active insulin-oligomer conjugate of formula insulin-OC—CH2—CH2—(OCH2CH2)3—OCH3.Type: GrantFiled: October 13, 2005Date of Patent: November 15, 2011Assignee: Biocon LimitedInventors: Nitesh Dave, Partha Hazra, Anuj Goel, Nita Roy, Anand Khedkar, Harish Iyer, Gautam Krishnan, H. S. Manjunath, Shrikumar Suryanarayan, Govindasamy Manikam, Goldy Sachdev, Mayank Garg
-
Patent number: 7884181Abstract: The invention provides a pharmaceutical formulation and a method for preparing the formulation.Type: GrantFiled: October 5, 2005Date of Patent: February 8, 2011Assignee: Novo Nordisk A/SInventors: Petter Lybeck (Berglund), Charlotte Hammelev, Lone Eskildsen, Johanne Madsen, Helle Aalund Olsen, Lone Kimer
-
Publication number: 20100233783Abstract: Process for purifying a recombinant protein including one or a few procedural steps only. The process combines the step of lysis of the host cell, with the purification of the protein of interest, allowing for a rapid and much more efficient process of purification. The conditions used during the purification process are those of a high temperature and a low pH, allowing for thermostable and acid-resistant recombinant proteins to be isolated from a suspension. The invention also relates to purifying recombinant proteins which are fusion proteins, wherein one part of the protein may be selected from an enamel matrix protein, such as amelogenin.Type: ApplicationFiled: March 23, 2006Publication date: September 16, 2010Applicant: Straumann Holding AGInventors: Johan Per Henrik Svensson, Leif Bülow
-
Patent number: 7763706Abstract: Described is a method for the preparation of a mixture of peptides, having an arginine and lysine content of at least 20 w/w %, based on the protein content, from at least one protein source, to a preparation comprising a mixture of arginine- and lysine-rich peptides, comprising at least 20 w/w % arginine and lysine, and to the use of the said preparation as active compound in a medicament, supplement, beverage or food product.Type: GrantFiled: July 11, 2003Date of Patent: July 27, 2010Assignee: Campina B.V.Inventors: Anita Dekker, Johanna Maria Henrica van der Steen
-
Publication number: 20100167374Abstract: The present invention relates to a chromatographic method of separating biological material comprising, providing chromatographic media comprising inorganic oxide particles having an average diameter of about 2 microns or less and an average pore diameter of 300 ? or more; applying a solvent comprising said biological material to said media, wherein said biological material is reversibly bonded to said media; and eluting said biological material from said media with a solvent in less than about 2 minutes for biological material having a molecular weight of less than about 100,000 Daltons.Type: ApplicationFiled: February 21, 2008Publication date: July 1, 2010Inventors: Reno T. Nguyen, Scott Anderson, Ian Chappell
-
Patent number: 7550558Abstract: This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.Type: GrantFiled: June 1, 2001Date of Patent: June 23, 2009Assignee: Fundacao de Ampara a Pesquiso do Estado de Sao Paolo (FAPESP)Inventors: Adilson Leite, Urara Kawazoe, Paulo Arruda, Arnaldo da Silva Junior
-
Patent number: 7534857Abstract: A biologically pure RNAIII inhibiting peptide (RIP), that includes five contiguous amino acids of the sequence YX2PX1TNF, where X1 is C, W, I or a modified amino acid, and X2 is K or S is provided. The RIP further includes amino acids having a sequence that differs from the sequence YX2PX1TNF by two substitutions or deletions, where X1 is C, W, I or a modified amino acid, and X2 is K or S. This agent offers improved protection against and treatment of staphylococcal infections, and related bacteria infections, in mammals.Type: GrantFiled: May 1, 2006Date of Patent: May 19, 2009Assignee: Centegen, Inc.Inventor: Naomi Balaban
-
Patent number: 7507787Abstract: A method of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a peptide is described. A method of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response. The method includes contacting cells with LPS, LTA, CpG DNA and/or intact microbe or microbial components in the presence or absence of a cationic peptide; detecting a pattern of polynucleotide expression for the cells in the presence and absence of the peptide, wherein the pattern in the presence of the peptide represents inhibition of an inflammatory or septic response. Also included are compounds and agents identified by the methods of the invention. In another aspect, the invention provides methods and compounds for enhancing innate immunity in a subject.Type: GrantFiled: December 2, 2002Date of Patent: March 24, 2009Assignee: The University of British ColumbiaInventors: Robert E. W. Hancock, B. Brett Finlay, Monisha Gough Scott, Dawn Bowdish, Carrie Melissa Rosenberger, Jon-Paul Steven Powers
-
Patent number: 7431936Abstract: The present invention provides the RSP-1 and RSP-2 proteins which are involved in the cytoadhesion of P. falciparum during ring-stage infection of erythrocytes, antibodies which bind to the proteins, methods of screening for a P. falciparum infection, methods of determining the infective stage of P. falciparum and vaccines for protecting individuals from Plasmodium sp. infections.Type: GrantFiled: November 29, 2002Date of Patent: October 7, 2008Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Juerg Gysin, Bruno Pouvelle, Artur Scherf, Pierre Buffet
-
Patent number: 7402653Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced thereform are also disclosed.Type: GrantFiled: June 16, 2006Date of Patent: July 22, 2008Assignee: CMS Peptides Patent Holding Company LimitedInventors: Wai Ming Wong, Kong Lam
-
Publication number: 20080139784Abstract: The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.Type: ApplicationFiled: July 8, 2005Publication date: June 12, 2008Applicant: Biocon LimitedInventors: Partha Hazra, H.S. Manjunath, Anand Khedkar, Harish Iyer, Nitesh Dave, Gautam Krishnan, Shrikumar Suryanarayan
-
Patent number: 7378390Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 ?.Type: GrantFiled: July 19, 2004Date of Patent: May 27, 2008Assignee: Novo Nordisk A/SInventors: Thomas Børglum Kjeldsen, Svend Ludvigsen
-
Publication number: 20080108787Abstract: This invention describes processes for purification of insulin or insulin-like material by reverse phase chromatography by using polystyrenic resins as the chromatographic materials. in particular the present invention describes processes for the purification of a particular insulin-like material from chemically and structurally similar contaminants.Type: ApplicationFiled: May 24, 2004Publication date: May 8, 2008Inventors: Maharaj K Sahib, Edupuganti B Raju, Sivaraman Subramaniam, Vennapusa R Reddy
-
Patent number: 7202044Abstract: The invention relates to defined peptides and the quantitative determination thereof in body fluids of patients suffering from progredient chronic dementia, in relation to the concentration of said peptides in a control group. The inventive peptides come from a protein precursor having the corresponding gene, are processed in a specific manner, and are optionally post-translationally modified, especially phosphorylized. An increase in the concentrations of these peptides or the corresponding non-processed protein indicates progredient chronic dementia. Progredient chronic dementia is detected by identifying the peptides and/or the protein individually or in combinations. The invention also relates to the use of said peptides for controlling the course of progredient chronic dementia and for the prognosis of progredient chronic dementia, especially for complementing or replacing mini-mental scores, and for developing therapeutic agents to combat progredient chronic dementia such as Alzheimer's disease.Type: GrantFiled: May 8, 2002Date of Patent: April 10, 2007Assignee: Biovision AGInventors: Norbert Lamping, Hans-Dieter Zucht, Harmut Selle, Michael Jürgens, Gabriele Heine, Rüdiger Hess
-
Patent number: 7193034Abstract: The invention provides methods and compositions useful for making synthetic peptide conjugates. In one embodiment, the invention provides compositions comprising the structure: wherein R is selected from lower substituted or unsubstituted alkyl, O, NH and S and P is an amine protection group. In more particular embodiments, the compositions comprise ?-amine protected 4,5-dehydroleucine or ?-amine protected (2S)-aminolevulinic acid and/or P is F-moc. These compounds may be incorporated into peptides, for example, peptides comprising a substituted or unsubstituted (2S)-aminolevulinic acid residue, such as (2S)-aminolevulinic acid residue is substituted with an O- or N-linked glycoconjugate, or a detectable label.Type: GrantFiled: September 6, 2005Date of Patent: March 20, 2007Assignee: Regents of the University of CaliforniaInventor: Carolyn R. Bertozzi
-
Patent number: 7094580Abstract: A method of perlecan isolation (from the EHS tumor) which produces “clean” (i.e. substantially “pure”) perlecan is disclosed. Clean perlecan is thus produced in sufficient quantities for use in a number of different in vitro and in vivo assays. In addition, this isolation method exploits a newly discovered aggregating property of a ˜220 kDa heparan sulfate proteoglycan (HSPG) observed during gel filtration chromatography, which allows it to be effectively separated from non-aggregating perlecan. The method employs specific cation exchange, anion exchange, molecular sieve chromatography and immobilized GAG affinity chromatography. It is demonstrated that there are no other contaminating proteins in the perlecan and HSPG preparations, and that the perlecan core protein is intact. Improved, clean perlecan based, rodent models of fibrillar amyloid protein deposition, accumulation and/or persistence in tissues are disclosed.Type: GrantFiled: December 18, 2002Date of Patent: August 22, 2006Assignee: University of WashingtonInventors: Gerardo Castillo, Alan D. Snow
-
Patent number: 7087408Abstract: Novel insulin precursors and insulin precursor analogs having a mini C-peptide comprising at least one aromatic amino acid residue have an increased folding stability. The novel insulin precursors and insulin precursor analogs can be expressed in yeast in high yields and are preferably not more 15 amino acid residues in length. Also provided are polynucleotide sequences encoding the claimed precursors or precursor analogs, and vectors and cell lines containing such polynucleotide sequences.Type: GrantFiled: December 11, 2002Date of Patent: August 8, 2006Assignee: Novo Nordisk A/SInventors: Thomas Borglum Kjeldsen, Svend Ludvigsen, Niels C. Kaarsholm
-
Patent number: 7074415Abstract: Streptococcus polypeptides and polynucleotides encoding them are disclosed. The polypeptides may be useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: June 20, 2001Date of Patent: July 11, 2006Assignee: ID Biomedical CorporationInventors: Josée Hamel, Catherine Ouellet, Nathalie Charland, Denis Martin, Bernard Brodeur
-
Patent number: 7041783Abstract: In accordance with the present invention, there are provided novel Survivin-binding-proteins (SBPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SBPs can be employed in a variety of ways, for example, for the production of anti-SBP antibodies thereto, in therapeutic compositions and in bioassays methods employing such proteins and/or antibodies. Also provided are transgenic non-human mammals that express the invention protein.Type: GrantFiled: January 24, 2002Date of Patent: May 9, 2006Assignee: The Burnham InstituteInventors: John C. Reed, Kazuya Okada
-
Patent number: 7037654Abstract: Probe sets for the multiplexed detection of the binding of, or interaction between, one or more ligands and target antiligands are provided. Detection involves the release of identifying tags as a consequence of target recognition. The probe sets include electrophoretic tag probes or e-tag probes, comprising a detection region and a mobility-defining region called the mobility modifier, both linked to a target-binding moiety. The probes comprise interactive functionalities adjacent the cleaved portion positioned in the probes such that the interactive functionality does not form part of the e-tag reporters. Target antiligands are contacted with a set of e-tag probes and the contacted antiligands are treated with a selected cleaving agent resulting in a mixture of e-tag reporters and uncleaved and/or partially cleaved e-tag probes. The mixture is exposed to a capture agent effective to bind to uncleaved or partially cleaved e-tag probes, followed by electrophoretic separation.Type: GrantFiled: November 9, 2001Date of Patent: May 2, 2006Assignee: Aclara Biosciences, Inc.Inventors: Ahmed Chenna, Sharat Singh
-
Patent number: 6939945Abstract: The invention provides methods and compositions useful for making synthetic peptide conjugates. In one embodiment, the invention provides compositions comprising the structure: wherein R is selected from lower substituted or unsubstituted alkyl, O, NH and S and P is an amine protection group. In more particular embodiments, the compositions comprise ?-amine protected 4,5-dehydroleucine or ?-amine protected (2S)-aminolevulinic acid and/or P is F-moc. These compounds may be incorporated into peptides, for example, peptides comprising a substituted or unsubstituted (2S)-aminolevulinic acid residue, such as (2S)-aminolevulinic acid residue is substituted with an O- or N-linked glycoconjugate, or a detectable label.Type: GrantFiled: October 10, 2002Date of Patent: September 6, 2005Assignee: The Regents of the University of CaliforniaInventors: Carolyn R. Bertozzi, Lisa A. Marcaurelle, Elena C. Rodriguez
-
Patent number: 6906028Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.Type: GrantFiled: October 3, 2002Date of Patent: June 14, 2005Assignee: Eli Lilly and CompanyInventors: Michael Rosario DeFelippis, Michael Allen Dobbins, Bruce Hill Frank, Shun Li, Dawn Marie Rebhun
-
Patent number: 6894023Abstract: A process for producing cation crystals of growth hormone or growth hormone derivatives, as well as growth hormone and growth hormone derivatives. The process of producing the growth hormone crystals includes the steps of (a) adding cations of inorganic or organic nature and an organic solvent or a mixture of inorganic solvents at a pH between 5.0 and 6.8 to a solution of growth hormone or derivatives. (b) growing growth hormone crystals at a temperature from about 0 to 30° C. and (c) isolating the cation crystals.Type: GrantFiled: June 12, 2000Date of Patent: May 17, 2005Assignee: Novo Nordisk A/SInventors: Flemming Junker, Claus Friis Theisen
-
Patent number: 6875589Abstract: A mini-proinsulin, in which the amino acid Arg bridges the A and the B chain instead of the C chain, shows insulin activity and is suitable for the preparation of pharmaceuticals for the treatment of diabetes mellitus. It can furthermore be converted into an insulin derivative simply using trypsin, the B chain of which is lengthened by Arg. This can be converted into insulin using carboxypeptidase B. Advantageously, however, the mini-proinsulin can also be converted to insulin directly in a one-pot process.Type: GrantFiled: March 10, 1995Date of Patent: April 5, 2005Assignee: Hoechst AktiengesellschaftInventors: Michael Dörschug, Paul Habermann, Gerhard Seipke, Eugen Uhlmann
-
Patent number: 6800606Abstract: Monomeric analogues of human insulin have a single substitution of the amino acid in 12th, 16th or the 26th position of the B chain of human insulin and may also have a terminal deletion in the B chain.Type: GrantFiled: March 8, 2002Date of Patent: October 5, 2004Assignee: Shanghai Institute of BiochemistryInventors: Feng You-Min, You-Shang Zhang
-
Patent number: 6727346Abstract: The present invention relates to an improved process for obtaining a precursor of an insulin or insulin derivative having correctly bonded cystine bridges in the presence of cysteine or cysteine hydrochloride and chaotropic auxiliary.Type: GrantFiled: September 7, 2001Date of Patent: April 27, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Franz-Josef Rubröder, Reinhold Keller
-
Publication number: 20040077528Abstract: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, i.e. undesirable components, from the peptide or protein. In a preferred embodiment, a peptide, such as insulin, containing one or more impurities, e.g., zinc ions, is entrapped in diketopiperazine to form a precipitate of peptide/diketopiperazine/impurity, which is then washed with a solvent for the impurity to be removed, which is a nonsolvent for the diketopiperazine and a nonsolvent for the peptide. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration.Type: ApplicationFiled: November 21, 2003Publication date: April 22, 2004Applicant: MannKind CorporationInventors: Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
-
Patent number: 6723321Abstract: Provided are compositions and methods useful for modulating the activity of autoinducer synthase catalysts. A method for identifing modulators of the autoinducer synthesis reaction is also provided. Such modulators are useful for controlling bacterial growth and can be used for therapeutic treatment of bacterial infections particularly in immunocompromised subjects. They are also useful in treating disease states associated with autoinducer synthesis and biofilm development.Type: GrantFiled: January 6, 1999Date of Patent: April 20, 2004Assignees: The Board of Trustees of the University of Illinois, The University of Iowa Research FoundationInventors: E. Peter Greenberg, John E. Cronan, Jr., Bryce V. Plapp, Matthew R. Parsek
-
Patent number: 6710167Abstract: The present invention relates to an improved procedure for the chromatographic purification of insulins wherein a pressure-stable organic polymeric chromatography material is used as a stationary phase, and the mobile phase contains at least one water-miscible organic solvent and at least one buffer substance and the pH is from about 7 to about 11.Type: GrantFiled: August 24, 1999Date of Patent: March 23, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Werner Sievers, Richard Bicker, Dieter Desch, Jörg Von Eysmondt, Reinhold Keller, Frank Richard
-
Publication number: 20030216543Abstract: Simulated moving beds for the chromatographic purification of insulin are provided. The insulin can be resolved from one or more components, using one or more simulated moving bed rings. Methods for designing simulated moving beds for the purification of insulin, and optimizing the operating parameters of the simulated moving beds, are also provided based upon the standing wave design.Type: ApplicationFiled: April 7, 2003Publication date: November 20, 2003Inventors: Nien-Hwa Linda Wang, Yi Xie, Sungyong Mun
-
Publication number: 20030191277Abstract: Novel insulin precursors and insulin precursor analogs having a mini C-peptide comprising at least one aromatic amino acid residue have an increased folding stability. The novel insulin precursors and insulin precursor analogs can be expressed in yeast in high yields and are preferably not more 15 amino acid residues in length. Also provided are polynucleotide sequences encoding the claimed precursors or precursor analogs, and vectors and cell lines containing such polynucleotide sequences.Type: ApplicationFiled: December 11, 2002Publication date: October 9, 2003Inventors: Thomas Borglum Kjeldsen, Svend Ludvigsen, Niels C. Kaarsholm
-
Publication number: 20030166834Abstract: Isolated polynucleotides encoding monkey Melanin Concentrating Hormone (MCH) Type 1 receptors and chimeric polypeptides are provided. Vectors and cells for recombinant expression of such MCH1R polypeptides, and isolated MCH1R polypeptides are also provided. MCH1R polynucleotides and polypeptides may be used, for example, to identify compounds that specifically interact with MCH receptor. Such compounds find use within therapies for humans and animals afflicted with conditions associated with MCH receptor activation.Type: ApplicationFiled: April 18, 2002Publication date: September 4, 2003Inventors: Michele Bennett Kinrade, Robbin Brodbeck, James Krause